Group 1 - The core viewpoint is that the current trend in innovative drugs is similar to the explosive logic of the CXO sector in 2018-2019, indicating a concentrated release of potential after long-term industry cultivation [1] - The innovative drug sector is expected to remain a strong asset with high confidence and significant space, particularly in oncology, weight loss, chronic disease iterations, and new unbroken fields [1][2] - The resurgence of the innovative drug market is driven by multiple factors, including a long adjustment period for the pharmaceutical sector, which may lead to valuation recovery [1] Group 2 - The period from 2025 to 2035 will see a concentration of patent expirations for major multinational pharmaceutical companies, providing an opportunity for Chinese innovative drugs to fill market gaps and gain a global competitive advantage [1] - The current phase of innovative drugs is at a critical turning point, with improving fundamentals indicating an objective trend that is independent of individual will [1] - The upgrade of Chinese innovative drugs is not a choice but a necessity, with the sector on the brink of releasing industrial dividends, emphasizing the importance of companies with real technological strength and clinical value [2]
永赢基金单林：创新药产业趋势清晰可见 关注肿瘤、减重、慢病迭代方向
Zhi Tong Cai Jing·2025-08-05 23:02